Use your antibodies-online credentials, if available.
抗Human MSH6 抗体:
抗Mouse (Murine) MSH6 抗体:
抗Rat (Rattus) MSH6 抗体:
Human Monoclonal MSH6 Primary Antibody for ELISA, WB - ABIN1724694
Lynch, Lynch: What the physician needs to know about Lynch syndrome: an update. in Oncology (Williston Park, N.Y.) 2005
Show all 2 Pubmed References
Human Polyclonal MSH6 Primary Antibody for ICC, IF - ABIN151794
Cyr, Heinen: Hereditary cancer-associated missense mutations in hMSH6 uncouple ATP hydrolysis from DNA mismatch binding. in The Journal of biological chemistry 2008
Show all 2 Pubmed References
Human Polyclonal MSH6 Primary Antibody for IHC, IP - ABIN151795
Masih, Kunnev, Melendy: Mismatch Repair proteins are recruited to replicating DNA through interaction with Proliferating Cell Nuclear Antigen (PCNA). in Nucleic acids research 2008
Show all 2 Pubmed References
Human Monoclonal MSH6 Primary Antibody for ELISA, WB - ABIN969292
Becker, Creagh, ONeill: Rab39a binds caspase-1 and is required for caspase-1-dependent interleukin-1beta secretion. in The Journal of biological chemistry 2009
Human Monoclonal MSH6 Primary Antibody for ICC, FACS - ABIN969293
Grindedal, Møller, Eeles, Stormorken, Bowitz-Lothe, Landrø, Clark, Kvåle, Shanley, Maehle: Germ-line mutations in mismatch repair genes associated with prostate cancer. in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009
Human Monoclonal MSH6 Primary Antibody for ELISA, WB - ABIN966596
Hess, Mendillo, Mazur, Kolodner: Biochemical basis for dominant mutations in the Saccharomyces cerevisiae MSH6 gene. in Proceedings of the National Academy of Sciences of the United States of America 2006
Cow (Bovine) Polyclonal MSH6 Primary Antibody for IHC, WB - ABIN2776759
Wedrén, Lovmar, Humphreys, Magnusson, Melhus, Syvänen, Kindmark, Landegren, Fermér, Stiger, Persson, Baron, Weiderpass: Estrogen receptor alpha gene polymorphism and endometrial cancer risk--a case-control study. in BMC cancer 2009
MSH6 Microsatellite Instability is associated with late stage Colorectal Cancer.
Our data demonstrate that two Lynch syndrome (LS) genes, MSH6 and PMS2, are associated with an increased risk for breast cancer and should be considered when ordering genetic testing for individuals who have a personal and/or family history of breast cancer
discover a translocation disrupting MLH1 and three mutations in MSH6 and PMS2 that increase endometrial, colorectal, brain and ovarian cancer risk
Whole exome sequencing in triple negative breast cancer cases revealed MSH6 rs2020912 (MAF: 56.25% vs. 1.04%, OR 122.13, 95% CI 12.29-2985.48) are risk factors for triple negative breast cancer.
CSE1L expression was correlated with MSH6 expression in tumor samples and was associated with poor prognosis in patients with osteosarcoma. Taken together, our results demonstrate that the CSE1L-MSH6 axis has an important role in osteosarcoma progression.
our data suggests thatMSH6 Glu39Gly polymorphism is associated with the risk of developing sporadic colorectal cancer in polish population. Linkage to the female gender, onset above 60 years old and further increase of risk when combined with wild-type allele of PMS2 IVS1-1121C >
Results from a study on gene expression variability markers in early-stage human embryos shows that is a putative expression variability marker for the 3-day, 8-cell embryo stage.
hMSH6 Glu39Gly polymorphism is associated with the risk of developing colorectal cancer in the Polish population.
Expression of MSH6 and MSH2 was positively associated with tumor volume doubling time. Gene expression was positively associated with ATR expression. Reduction of MSH6 and MSH2 expression at the messenger RNA and protein levels could be involved in direct Pituitary Adenoma proliferation by promoting cell-cycle progression or decreasing the rate of apoptosis through interference with the function of the ATR-Chk1 pathway.
Our results suggest that increased expression of MSH6, or other MMR, may be a new mechanism contributing to the acquired resistance during TMZ therapy; and may serve as an indicator to the resistance in GBM.
study to estimate frequency of point mutations and chromosomal rearrangements in 3 mismatch repair (MMR) genes MLH1, MSH2, and MSH6 among unselected patients with ovarian cancer; estimate that approximately 0.6% of unselected ovarian cancer patients have mutations in the MMR genes
MSH6 frameshift variants incompletely segregate with the Lynch syndrome phenotype in two families.
Patients with mutations 6 showed higher rate of achieving major molecular response than those<6 (P=0.0381). Mutations in epigenetic regulator, ASXL1, TET2, TET3, KDM1A and MSH6 were found in 25% of patients. TET2 or TET3, AKT1 and RUNX1 were mutated in one patient each. ASXL1 was mutated within exon 12 in three cases
The MSH6 gene polymorphisms are likely to play an important role in the progression of AIDS in the northern Chinese population.
MSH6 mutations contribute to colorectal cancer susceptibility in Algerian families with suspected Lynch syndrome.
Neoadjuvant therapy in microsatellite-stable colorectal carcinoma induces concomitant loss of MSH6 and Ki-67 expression.
High MSH6 expression is associated with the development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
In path_MSH6 10-year survival was 84%, relative incidence of subsequent cancer compared with incidence of first cancer was slightly but insignificantly higher than cancer incidence in patients with Lynch syndrome without previous cancer.
human Pol alpha interacts with MSH2-MSH6 complex
In colorectal neoplasms, negative expression of the MMR proteins MLH1, MSH2 or MSH6 was seen in 15% (47 of 313) of the patients. Defect MLH1 was most common and detected in 12% of the cases. Defect MLH1 and MSH2 were identified in each patient's normal adjacent mucosa.
Studied MSH6 gene expression in developing zebrafish and the influence of MSH6 expression on the production of mismatch binding factors.
Identification and characterization of novel knockout mutants of the three major MMR genes, mlh1, msh2, and msh6, in zebrafish that develop tumors at low frequencies.
we show that AID binds cooperatively with UNG and the mismatch repair proteins Msh2-Msh6 to Ig Smu and Sgamma3 regions
Data suggest that MSH6 protects B cells from neoplastic transformation by preserving genomic stability.
similar defects on switching in Msh2(-/-), Msh2(-/-)Msh6(-/-) and Msh2(-/-)Msh6(-/-)Msh3(-/-) mice confirm that MutSalpha but not MutSbeta plays an important role in class switch recombination
Msh6 deficiency resulted in somatic instability of a (GTG)84 repeat.
role for Msh6 in protective cellular responses of primary cells to ultraviolet-B-induced mutagenesis and, hence, the prevention of skin cancer.
Data suggest that MutS homologues Msh2, Msh3, and Msh6 play overlapping and distinct roles during antibody diversification processes.
Data suggest that activation-induced cytidine deaminase has limited entry points into V and S regions in vivo, and subsequent mutation requires Msh2-Msh6, but not Msh3, and DNA polymerase.
Mice nullizygous for both Msh2 and Msh3 and those nullizygous for both Msh3 and Msh6 displayed the greatest overall increases in mutation frequencies compared with wild-type mice.
in Msh6(-/-)Ung(-/-) mice, mutations were mostly C,G transitions and class switch recombination was greatly reduced.
p53 and Msh6 are functionally interrelated and these tumor suppressors act together to accelerate tumorigenesis.
These findings indicate that MutS alpha reduces spontaneous and IR-induced mutation in a cell type-dependant manner.
Synergism between Mgmt and Msh6 can be explained entirely by the suppression of alkylation-induced apoptosis when Msh6 is absent.
ablation of either Msh6 or Exo1 function in the Mgmt-null mouse renders these rapidly proliferating tissues alkylation-resistant. The Msh6 defect confers total alkylation resistance
This gene encodes a protein similar to the MutS protein. In E. coli, the MutS protein helps in the recognition of mismatched nucleotides, prior to their repair. A highly conserved region of approximately 150 aa, called the Walker-A adenine nucleotide binding motif, exists in MutS homologs. The encoded protein of this gene combines with MSH2 to form a mismatch recognition complex that functions as a bidirectional molecular switch that exchanges ADP and ATP as DNA mismatches are bound and dissociated. Mutations in this gene have been identified in individuals with hereditary nonpolyposis colon cancer (HNPCC) and endometrial cancer.
DNA mismatch repair protein Msh6
, G/T mismatch-binding protein
, mutS-alpha 160 kDa subunit
, sperm-associated protein
, mutS homolog 6 (E. coli)
, DNA mismatch repair protein Msh6-like
, g/T mismatch-binding protein
, LOW QUALITY PROTEIN: DNA mismatch repair protein Msh6